# Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

> **NCT02563327** · PHASE3 · COMPLETED · sponsor: **Centers for Disease Control and Prevention** · enrollment: 53 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** Rifapentine
- **DRUG:** Moxifloxacin
- **DRUG:** Rifampin
- **DRUG:** Isoniazid
- **DRUG:** Pyrazinamide
- **DRUG:** Ethambutol
- **DIETARY_SUPPLEMENT:** Pyridoxine

## Key facts

- **NCT ID:** NCT02563327
- **Lead sponsor:** Centers for Disease Control and Prevention
- **Sponsor class:** FED
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-30
- **Primary completion:** 2021-08-30
- **Final completion:** 2021-08-30
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02563327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02563327, "Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02563327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*